☆ 4.5 Editorial Material

The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease

DIGESTIVE AND LIVER DISEASE (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease- a retrospective study

Moran Livne-Margolin et al.

Summary: This study compared the effectiveness of vedolizumab and ustekinumab in treating extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) patients, and found no significant difference between the two in terms of EIM treatment.

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Gastroenterology & Hepatology

The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study

Cara De Galan et al.

Summary: This study compared the effects of vedolizumab and ustekinumab on articular extra-intestinal manifestations. The results showed no significant differences in the deterioration of pre-existing arthropathy and the rate of new-onset arthropathy between the two treatments. Patients taking vedolizumab had a higher risk of developing new arthralgia within 6 months, but this effect was not sustained during the 2-year follow-up.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease

Jurij Hanzel et al.

Summary: In Crohn's disease and ulcerative colitis patients, extraintestinal manifestations can affect up to 50% of patients, mainly involving the musculoskeletal system and skin, with less common involvement of the hepatobiliary tract and eye. The pathophysiology of EIMs is poorly understood but may involve abnormal immune responses and cross-reactivity with self-antigens. Tumor necrosis factor antagonists have shown efficacy in treating EIMs, while vedolizumab's efficacy in treating EIMs remains uncertain.

DRUGS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review

Lucas Guillo et al.

Summary: Ustekinumab has shown effectiveness in treating EIMs, especially for dermatological and rheumatological manifestations, but more data are needed to confirm its role in this setting.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

Vince B. C. Biemans et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Letter Gastroenterology & Hepatology

Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease

Thomas Chateau et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Brian G. Feagan et al.

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Letter Rheumatology

Comment on: Emergence of severe spondyloar-thropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

Stefano Alivernini et al.

RHEUMATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

Claire Liefferinckx et al.

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Review Gastroenterology & Hepatology

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

Thomas Chateau et al.

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Article Rheumatology

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Atul Deodhar et al.

ARTHRITIS & RHEUMATOLOGY (2019)

Add to Collection

Article Dermatology

Ustekinumab treatment for hidradenitis suppurativa

Kana Takeda et al.

JOURNAL OF DERMATOLOGY (2019)

Add to Collection

Review Ophthalmology

Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

Kathryn L. Pepple et al.

OPHTHALMOLOGY (2018)

Add to Collection

Review Gastroenterology & Hepatology

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases

Hang Hock Shim et al.

JGH OPEN (2018)

Add to Collection

Article Rheumatology

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Arthur Kavanaugh et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

Add to Collection

Review Gastroenterology & Hepatology

Paradoxical inflammation induced by anti-TNF agents in patients with IBD

Isabelle Cleynen et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)

Add to Collection

Article Dermatology

Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab

Emmanuella Guenova et al.

ARCHIVES OF DERMATOLOGY (2011)

Add to Collection

Article Immunology

Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease

DH Adams et al.

NATURE REVIEWS IMMUNOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.